Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.
Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are the two important checkpoint molecules with great potential in targeted cancer therapy. Several antibodies targeting PD-1 and PD-L1 have been approved for clinical use. In this review, we focus on the recent development of targeting PD-1 and PD-L1 in gastric cancer (GC) therapy.
Department of Medical Oncology, First Hospital of Lanzhou University, Lanzhou, China.
Xiaojun
X
Liu
Department of Infectious Diseases, First Hospital of Lanzhou University, Lanzhou, China.
Zhongxia
Z
Yang
Storr Liver Centre, Westmead Institute for Medical Research, Western Clinical School of the Faculty of Medicine at Westmead Hospital, University of Sydney, Australia.
Olivier
O
Latchoumanin
Storr Liver Unit, Westmead Institute for Medical Research, University of Sydney at Westmead Hospital, NSW 2145, Australia.
Liang
L
Qiao
gastric cancer; immune checkpoint molecules; programmed death ligand-1; programmed death-1